The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of TA998: Risankizumab for treating moderately to severely active ulcerative colitis.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for 2 weeks and will close at 5pm on Wednesday 11th September 2024. Take part by visiting the consultations page.